- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | BiomX addresses FDA queries on nebulizer for CF treatment | 4 | Investing.com | ||
| 17.10. | BiomX reagiert auf FDA-Anfragen zu Vernebler für Mukoviszidose-Therapie | 8 | Investing.com Deutsch | ||
| 17.10. | BiomX Inc: BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways | 5 | GlobeNewswire (USA) | ||
| 19.08. | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis | 533 | GlobeNewswire (Europe) | U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification... ► Artikel lesen | |
| 13.08. | BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study | 1 | Seeking Alpha | ||
| 13.08. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | BiomX GAAP EPS of -$0.19 | 3 | Seeking Alpha | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 13.08. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | BiomX Inc: BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates | 345 | GlobeNewswire (Europe) | Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications... ► Artikel lesen | |
| 12.08. | What to Expect from BiomX's Earnings | 1 | Benzinga.com | ||
| 06.08. | BiomX Inc: BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 30.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins | 3 | Investing.com | ||
| 15.07. | BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target | 1 | Investing.com | ||
| 14.07. | BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy | 2 | Investing.com | ||
| 14.07. | BiomX-Aktie schießt nach Start von Phase-2b-Studie für Mukoviszidose-Therapie in die Höhe | 4 | Investing.com Deutsch | ||
| 14.07. | BiomX startet Phase-2b-Studie mit Phagentherapie gegen Infektionen bei Mukoviszidose | 1 | Investing.com Deutsch | ||
| 14.07. | BiomX begins phase 2b trial for phage therapy targeting CF infections | 1 | Investing.com | ||
| 14.07. | BiomX Inc: BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis | 215 | GlobeNewswire (Europe) | First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,45 | -0,66 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| AMGEN | 249,30 | -0,40 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,100 | -3,67 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,066 | +2,11 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
23.10.2025 / 12:51 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,874 | +4,23 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| REDHILL BIOPHARMA | 1,570 | 0,00 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| FIBROGEN | 9,100 | -0,55 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| VAXCYTE | 37,000 | -3,65 % | Vaxcyte, Inc.: Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services | New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif.... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 3,180 | -1,85 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union | - EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock | NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA"), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,97 | 0,00 % | Biotech-Boom: Novartis übernimmt Avidity Biosciences für 12 Milliarden US$ | Der Schweizer Pharmakonzern Novartis hat einen bedeutenden Schritt in der Erweiterung seines Portfolios gemacht. Mit der Übernahme des US-Biotechnologieunternehmens Avidity Biosciences stärkt Novartis... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday |
Das Unternehmen BIOMX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,586 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.